REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug
Replimune stock surges after the company aligned with the FDA on plans to resubmit its BLA for RP1 plus Opdivo in advanced melanoma.
Zacks
More News
Why Is Replimune Stock Gaining Monday?
Replimune Group (REPL) shares gain on key RP2 & RP1 oncology data presentations at ASCO. Read the clinical trial results.read more...
Benzinga
Why Is REPL Stock Gaining In Pre-Market Today?
Replimune shares gained ahead of its fourth-quarter earnings report, following positive human-trial data of its immunotherapy RP2.
Stocktwits
Replimune, Dell Technologies, NetApp And Other Big Stocks Moving Higher on Friday
US stocks up, Dow Jones up 171 pts. Replimune Group rises after FDA agreement. Other big gainers include Dell, NetApp, and Okta.read more...
Benzinga
REPL Stock Shot Up 80% Today – What’s The Deal With FDA?
Replimune announced it has reached an agreement with the U.S. Food and Drug Administration to resubmit a marketing application for RP1 in combination with Nivolumab to treat advanced melanoma.
Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire
REPL, QURE Stocks Rise Amid Makary’s Reported Resignation As FDA Chief
The New York Times reported that Makary’s departure was driven in large part by his strong opposition to the administration’s decision to authorize fruit-flavored e-cigarettes.
Stocktwits
REPL, QURE, MRNA Soar On Reports Trump Will Fire FDA’s Marty Makary
The Wall Street Journal reported on the plans on Friday, citing people familiar with the matter, while noting that other top administration officials believe Makary is struggling to manage his agency.
Stocktwits
REPL Nosedives As FDA Chief Stands Firm Against Melanoma Treatment: ‘I Don’t Work For Replimune…’
FDA refused to approve Replimune’s melanoma drug RP1 for the second time in April, citing insufficient data to provide “substantial evidence of effectiveness” in the treatment of unresectable advanced cutaneous melanoma.
In trading on Monday, biotechnology shares were relative leaders, up on the day by about 2.1%. Leading the group were shares of Insight Molecular Diagnostics, up about 22.8% and shares of Replimune...